CMPI insider filings
Checkmate Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-05-31. Screen CMPI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CMPI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Checkmate Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-05-31 | 4 | Isacoff Oren — Director | Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2022-05-31 | 4 | Colabuono Peter — Director | Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2022-05-31 | 4 | Yan Joy — Director | Disposition to issuer (D): 20,061 (derivative) | EDGAR |
| 2022-05-31 | 4 | Dolski Robert — Chief Financial Officer | Disposition to issuer (D): 101,180 (derivative) · Disposition to issuer (D): 27,300 (derivative) · Disposition to issuer (D): 150,000 (derivative) | EDGAR |
| 2022-05-31 | 4 | Wooldridge James — Chief Medical Officer | Disposition to issuer (D): 54,600 (derivative) · Disposition to issuer (D): 101,180 (derivative) · Disposition to issuer (D): 27,300 (derivative) · Disposition to issuer (D): 150,818 (derivative) · Disposition to issuer (D): 95,916 (derivative) | EDGAR |
| 2022-05-31 | 4 | BASH ALAN — Chief Executive Officer, Director | Disposition to issuer (D): 575,000 (derivative) | EDGAR |
| 2022-05-31 | 4 | Wigginton Jon Marc — Director | Disposition to issuer (D): 20,061 (derivative) | EDGAR |
| 2022-05-31 | 4 | Flaherty Keith T. — Director | Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 4,012 (derivative) · Disposition to issuer (D): 22,736 (derivative) | EDGAR |
| 2022-05-31 | 4 | Fuhrman Alan — Director | Disposition to issuer (D): 246,671 (derivative) · Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 22,736 (derivative) | EDGAR |
| 2022-05-31 | 4 | POWELL MICHAEL — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2022-05-17 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 35,850 @ $10.45 · Sale (S): 95,800 @ $10.45 | EDGAR |
| 2022-05-12 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 18,676 @ $10.38 · Sale (S): 17,700 @ $10.38 · Sale (S): 124,525 @ $10.39 | EDGAR |
| 2022-05-09 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 20,743 @ $10.37 · Sale (S): 48,334 @ $10.37 · Sale (S): 17,600 @ $10.37 | EDGAR |
| 2022-05-04 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 153,700 @ $10.38 · Sale (S): 79,475 @ $10.37 · Sale (S): 37,500 @ $10.37 | EDGAR |
| 2022-04-29 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 47,396 @ $10.38 · Sale (S): 73,400 @ $10.38 · Sale (S): 69,230 @ $10.38 | EDGAR |
| 2022-04-28 | 4 | Wooldridge James — Chief Medical Officer | Grant/award (A): 54,600 (derivative) @ $0 | EDGAR |
| 2022-04-26 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 37,430 @ $10.39 · Sale (S): 27,668 @ $10.39 · Sale (S): 64,683 @ $10.38 | EDGAR |
| 2022-04-21 | 4 | venBio Global Strategic Fund II L.P. — 10% owner venBio Global Strategic GP II, L.P. — 10% owner venBio Global Strategic GP II, Ltd. — 10% owner GOODMAN COREY S — 10% owner Adelman Robert J — 10% owner | Sale (S): 399,923 @ $10.42 · Sale (S): 85,611 @ $10.39 · Sale (S): 62,200 @ $10.38 | EDGAR |
| 2022-03-02 | 4 | BASH ALAN — Chief Executive Officer, Director | Grant/award (A): 575,000 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 1,820 @ $2.90 · Sale (S): 5,990 @ $2.83 · Sale (S): 300 @ $2.70 | EDGAR |
| 2022-02-01 | 4 | Wigginton Jon Marc — Director | Grant/award (A): 20,061 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Dolski Robert — Chief Financial Officer | Grant/award (A): 101,180 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Wooldridge James — Chief Medical Officer | Grant/award (A): 101,180 (derivative) @ $0 | EDGAR |
| 2021-12-17 | 4 | Yan Joy — Director | Grant/award (A): 20,061 (derivative) @ $0 | EDGAR |
| 2021-10-29 | 4 | Fuhrman Alan — See Remarks, Director | Grant/award (A): 246,671 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | POWELL MICHAEL — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-08-06 | 4 | Dolski Robert — Chief Financial Officer | Grant/award (A): 27,300 (derivative) @ $0 | EDGAR |
| 2021-08-06 | 4 | Wooldridge James — Chief Medical Officer | Grant/award (A): 27,300 (derivative) @ $0 | EDGAR |
| 2021-08-06 | 4 | Chaudhary Kleem — Chief Business Officer | Grant/award (A): 27,300 (derivative) @ $0 | EDGAR |
| 2021-08-06 | 4 | Labinger Barry — President and CEO, Director | Grant/award (A): 85,950 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Isacoff Oren — Director | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Colabuono Peter — Director | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Flaherty Keith T. — Director | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 7,224 @ $6.04 | EDGAR |
| 2021-06-21 | 4 | Fuhrman Alan — Director | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | POWELL MICHAEL — Director | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 3,578 @ $6.18 | EDGAR |
| 2021-06-01 | 4 | Krieg Arthur M — Chief Scientific Officer | Other (J): 68,457 @ $0 · Other (J): 68,457 @ $0 · Other (J): 68,457 @ $0 | EDGAR |
| 2021-05-19 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 25,001 @ $6.97 | EDGAR |
| 2021-03-31 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 17,468 @ $10.94 · Purchase (P): 15,752 @ $11.40 | EDGAR |
| 2021-03-29 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 10,036 @ $12.35 · Purchase (P): 3,484 @ $12.15 | EDGAR |
| 2021-03-01 | 4 | Chaudhary Kleem — Chief Business Officer | Option exercise (M): 2,000 @ $2.62 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2021-01-28 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 1,701 @ $13.05 | EDGAR |
| 2021-01-21 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 500 @ $13.09 | EDGAR |
| 2021-01-15 | 4 | Chaudhary Kleem — Chief Business Officer | Option exercise (M): 2,000 @ $2.62 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2020-12-31 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 443 @ $14.16 | EDGAR |
| 2020-12-23 | 4 | Chaudhary Kleem — Chief Business Officer | Option exercise (M): 4,000 @ $2.62 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 5,103 @ $14.64 | EDGAR |
| 2020-12-17 | 4 | Krieg Arthur M — Chief Scientific Officer | Purchase (P): 42 @ $14.49 · Purchase (P): 4,805 @ $14.62 | EDGAR |
| 2020-11-12 | 4 | POWELL MICHAEL — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Checkmate Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-05-31 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-02-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-02-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-12-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-12-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CMPI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs